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lymphoblastic leukemia
ABSTRACT
Introduction. Controversial data on disturbances in mineral homeostasis and bone mass were reported in 
children with diagnosed untreated acute lymphoblastic leukemia (ALL). Early detection of bone metabolism 
abnormalities is important for monitoring the effect of therapy on the skeleton. The purpose of this study 
was to evaluate bone metabolism in children and adolescents with newly diagnosed acute lymphoblastic 
leukemia by assessing biomarkers of bone cell activity. 
Materials and methods. Propeptide of type 1 procollagen (P1NP) and osteocalcin (OC) as bone formation 
markers and C-terminal telopeptide of type 1 collagen (CTX) and tartrate resistant acid phosphatase 5b 
(TRAP 5b) as resorption markers were determined in 22 Caucasian children and adolescents (12 boys 
4–21 years, 10 girls 4–16 years) with newly diagnosed, untreated ALL and in 22 age- and gender-matched 
controls. 
Results. Bone formation, in particular, and bone resorption were significantly reduced in ALL children and 
adolescents compared with controls (Me P1NP 51.9 vs. 433.4 μg/L and OC 16.1 vs. 80.5 μg/L; p < 0.0001; 
Me CTX 0.454 vs. 1.225 μg/L and TRAP 5b 2.8 vs. 5.6 U/L; p < 0.001). P1NP positively correlated with OC 
(r = 0.56; p = 0.01) and CTX correlated with TRAP 5b (r = 0.54; p = 0.02) in children and adolescents with 
ALL. Median P1NP and OC concentrations in ALL children (4–9 years) were dramatically reduced compared 
with the healthy ones (10-fold and 9-fold respectively), whereas in adolescents with ALL (10–21 years) 
both bone formation markers were reduced in a lesser degree in comparison with the healthy adolescents. 
Conclusions. Acute lymphoblastic leukemia influences bone metabolism which is strongly related to the 
age of onset. More significant disturbances in bone turnover, particularly in bone formation (suppression of 
collagen synthesis), are observed in children with untreated ALL in comparison with adolescents with ALL.
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Introduction
Acute lymphoblastic leukemia (ALL) is the most 
prevalent form of curable malignant disease found in 
children and has increasing numbers of survivors. Dis-
turbances in mineral homeostasis and bone mass in 
children with diagnosed ALL were reported by Atkinson 
et al. over 20 years ago [1]. In children with ALL at di-
agnosis, the predominant features of bone metabolism 
are: reduced bone mineral density accompanied by 
suppressed bone formation, reflected by low turnover 
of bone collagen and other bone formation markers [2]. 
On the other hand, the data on bone resorption markers 
are inconsistent showing reduced, normal or increased 
values [2–6].
Vertebral fractures at diagnosis of ALL in children 
are an uncommon problem, whereas osteopenia and 
osteoporosis, as late consequences of treatment in 
childhood and adolescence, are common. However, the 
information on the mechanisms involved in abnormal 
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bone metabolism is still insufficient. Disturbances in 
systemic growth hormone axis, hyperleptinemia and 
vitamin D deficiency have been reported to play a role 
in bone remodeling in association with acute lympho-
blastic leukemia. Children with ALL show decreased 
bone volume and diminished number of bone cells [4]. 
The purpose of this study was to evaluate bone 
metabolism in children and adolescents with newly 
diagnosed acute lymphoblastic leukemia by assessing 
biomarkers of bone cells activity.
Patients and control subjects
22 Caucasian children and adolescents (12 boys 
aged 4–21 years, 10 girls aged 4–16 years) with newly 
diagnosed, untreated acute lymphoblastic leukemia 
(ALL) recruited from Department of Pediatrics, Hema-
tology and Oncology, Collegium Medicum, Nicolaus 
Copernicus University were included in the study. We 
excluded those who suffered from chronic diseases and 
had taken medicines known to affect bone metabolism. 
The patients were divided into two groups: ALL children 
(age range 4–9 years; 8 girls and 4 boys) and ALL ado-
lescents (age range 10–21 years; 2 girls and 8 boys). 
All patients after diagnosis were treated according to 
the Non-B ALL BFM 90 protocol. 
Age- and gender-matched control group included 
12 boys aged 4–21 years and 10 girls aged 3–16 years 
(C). Control group consisted of healthy children and 
adolescents which were recruited from the general pop-
ulation. The inclusion criteria were: height, weight within 
the 3rd and 97th percentile, lack of systemic illnesses, 
endocrine or renal disorders, chronic diseases, obesity, 
no medicines known to affect bone metabolism. None 
of them was receiving any medication. They showed 
normal physical development. Controls were also 
divided into two groups: healthy children (median age 
5.3 years; 8 girls and 4 boys) and healthy adolescents 
(median age 14.4 years; 2 girls and 8 boys). 
The study was approved by the Ethics Committee, 
Collegium Medicum, N.C. University. 
Materials and methods
Venous fasting blood was collected between 
7.00 and 9.00 a.m. to avoid any bias from diurnal 
variation. Blood was centrifuged, immediately after 
clotting, at 1500 g, 4°C for 15 min. to obtain serum. 
Serum samples were frozen at –70°C and stored until 
the assays were run. 
Serum propeptide of type 1 procollagen (P1NP), 
osteocalcin (OC) as bone formation markers and C-ter-
minal telopeptide of type 1 collagen (CTX) as resorption 
markers were assayed by ECLIA on clinical chemistry 
analyzer (Elecsys, Roche Diagnostics). Tartrate resis-
tant acid phosphatase 5b (TRAP 5b) was measured by 
ELISA (Metra® TRAP5b EIA Kit Quidel Corp.).
Elecsys Total P1NP bone formation marker (total 
procollagen type 1 N-terminal propeptide) detects the 
serum concentration of total P1NP and reflects changes 
in synthesis of new type 1 collagen; detection limit is 
5 µg/L; measuring range 5–1200 µg/L. The OC assay 
detects total osteocalcin (intact and N-MID fragment) 
released by osteoblasts to the circulation; detection limit 
is 0.5 µg/L; measuring range 0.5–300.0 µg/L. CTX meth-
od is based on highly specific monoclonal antibody 
against a b-aspartate isomerized form of the sequence 
EKAHD-b-GGR derived from the C-terminal telopeptide 
region of the type I collagen a-1 chain; detection limit is 
0.01 µg/L; measuring range 0.01–6.0 µg/L. TRAP 5b was 
determined in serum by immunocapture enzyme assay 
in which two unique monoclonal antibodies, Trk49 and 
Trk62, were used. Trk49 is highly specific to inactive 
TRAP5b fragments. Antibody Trk62 is highly specific 
to intact, active TRAP5b. Trk49 binds inactive TRAP5b 
fragments, thereby making Trk62 more available to bind 
active TRAP5b; assay sensitivity is 0.2 U/L; inter-assay 
CV 2.0–3.0% (for activity 3.8–7.4 U/L); intra-assay CV 
1.9–2.2% (for activity 3.4–7.4 U/L). 
Data were expressed as medians (25th and 75th 
percentiles). Normal distribution of the analyzed vari-
ables was tested by Shapiro-Wilk test. Spearman rank 
correlation tests and Mann-Whitney U-test were used. 
P values ≤ 0.05 were considered statistically significant.
Results
Bone formation, in particular, and resorption markers 
were significantly reduced in children and adolescents 
with untreated acute lymphoblastic leukemia (ALL) 
compared with healthy children and adolescents. Bio-
chemical bone turnover markers concentrations or 
activity in study participants were shown in Table 1. The 
median age was 8.0 (4.0–14.0) yrs for patients with 
diagnosed ALL and 8.0 (5.0–14.4) yrs for age-matched 
controls. Patients with acute lymphoblastic leukemia at 
diagnosis (ALL) had over 8-fold lower P1NP concen-
tration than controls (C). OC concentration at onset of 
ALL was also very low compared with that of controls 
(16.1 vs. 80.5 µg/L, p < 0.0001). Similarly, CTX and 
TRAP 5b were significantly lower (0.454 vs. 1.225 µg/L, 
p < 0.001; 2.8 vs. 5.6 U/L, p < 0.001 respectively). P1NP 
positively correlated with OC (r = 0.56, p = 0.008) and 
CTX with TRAP 5b (r = 0.54, p = 0.02) in children and 
adolescents with ALL. Significant positive correlations 
were also found between P1NP and OC, CTX, TRAP 5b 
in healthy children and adolescents (r = 0.67, p = 0.002; 
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Gender (F/M) 10/12 10/12 ns
Age (yrs) 8.0 (4.0–14.0) 8.0 (5.0–14.4) ns
P1NP [µg/L] 51.9 (41.5–152.1) 433.4 (372.8–748.4) < 0.0001
OC [µg/L] 16.1 (7.7–34.1) 80.5 (46.7–126.8) < 0.0001
CTX [µg/L] 0.454 (0.302–0.607) 1.125 (0.952–1.550) < 0.001
TRAP 5b [U/L] 2.8 (0.7–4.4) 5.6 (5.1–7.9) < 0.001
ALL — acute lymphoblastic leukemia; P1NP — propeptide of type 1 procollagen; OC — osteocalcin; CTX — C-terminal telopeptide of type 1 col-
lagen; TRAP 5b — tartrate resistant acid phosphatase 5b 
Table 2. Biochemical bone turnover markers in children with untreated acute lymphoblastic leukemia (ALL) and 







Gender (F/M) 8/4 8/4 ns
Age (yrs) 4.5 (4.0–5.0) 5.3 (4.0–6.0) ns
P1NP [µg/L] 46.4 (41.5–152.1) 435.7 (407.6–517.9) < 0,0001
OC [µg/L] 8.5 (5.9–23.6) 74.9 (65.7–104.0) < 0,0001
CTX [µg/L] 0.422 (0.333–0.474) 1.126 (0.993–1.550) < 0,0001
TRAP 5b [U/L] 3.4 (1.3–5.0) 6.4 (5.5–7.5) 0,003
ALL — acute lymphoblastic leukemia; P1NP — propeptide of type 1 procollagen; OC — osteocalcin; CTX — C-terminal telopeptide of type 1 col-
lagen; TRAP 5b — tartrate resistant acid phosphatase 5b 
r = 0.69, p = 0.0001; r = 0.60, p = 0.006 respective-
ly) and between OC and CTX, TRAP 5b (r = 0.76, 
p = 0.001; r = 0.58, p = 0,005 respectively). CTX 
positively correlated with TRAP 5b in controls (r = 0.53, 
p = 0.02).
Next, ALL patients and controls were divided into 
groups according to age (Tab. 2 and Tab. 3). All de-
termined biochemical bone turnover markers were 
significantly reduced in prepubertal ALL children com-
pared with controls. Me P1NP was 9.4-fold lower in ALL 
children compared with the healthy ones (p < 0.0001). 
Similarly, OC concentration was 8.8-fold lower in leuke-
mic children in comparison with healthy children at the 
same age (p < 0.0001). However, in prepubertal group 
CTX concentration and TRAP 5b activity were only 3-fold 
lower in ALL children than in controls (p < 0.0001 and 
p < 0.003 respectively).
Similarly, in adolescents with ALL, P1NP and OC 
concentrations were almost 6-fold and almost 5-fold 
lower (p < 0.03 and p < 0.01 respectively) in compar-
ison with the healthy ones. In ALL adolescents, CTX 
concentration and TRAP 5b activity were significantly 
lower than in controls (p < 0.03).
Discussion
Bone turnover in children reflects bone remodeling 
in which bone formation dominates over bone resorp-
tion. The pathogenesis of bone loss relates to an imbal-
ance between resorption and formation with the excess 
of the former over formation of bone [7]. Early detection 
of abnormalities in bone turnover may be facilitated by 
assessing biomarkers of bone metabolism, including 
vitamin D status. Bone turnover markers reflect the ac-
tual status of bone metabolism. In many children with 
cancer, biomarkers of bone formation (osteocalcin, 
bone specific alkaline phosphatase and carboxy-(or 
N-terminal) propeptide of type 1 procollagen) were ob-
served to be suppressed, while bone resorption markers 
were elevated as measured by serum cross-linked (or 
C-terminal) telopeptide of type 1 collagen. Insulin-like 
growth factor 1, which stimulates bone formation, may 
be suppressed indirectly indicating a growth hormone 
insufficiency. Leptin may also play a role in bone remod-
eling as hyperleptinemia has been observed in associ-
ation with acute lymphoblastic leukemia. Evaluation of 
bone status using such biomarkers is complicated by 
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Table 3. Biochemical bone turnover markers in adolescents with untreated acute lymphoblastic leukemia (ALL) and 







Gender (F/M) 2/8 2/8 ns
Age (yrs) 14.0 (12.0–16.0) 14.4 (12.0–16.0) ns
P1NP [µg/L] 73.3 (51.9–121.3) 431.0 (99.3–975.3) < 0.03
OC [µg/L] 21.1 (16.1–44.6) 100.1 (43.6–126.8) < 0.01
CTX [µg/L] 0.485 (0.302–0.938) 1.275 (0.557–1.510) < 0.03
TRAP 5b [U/L] 1.6 (0.7–4.2) 5.5 (2.4–7.9) < 0.03
ALL — acute lymphoblastic leukemia; P1NP — propeptide of type 1 procollagen; OC — osteocalcin; CTX — C-terminal telopeptide of type 1 col-
lagen; TRAP 5b — tartrate resistant acid phosphatase 5b 
the lack of universally accepted reference values and 
the variation of age, gender, or pubertal status. Etiologic 
factors contributing to the observed skeletal morbidities 
include disease process, chemotherapy (drugs such 
as glucocorticoids and methotrexate) and radiother-
apy. Other factors common to children with cancer, 
such as chronic inflammation, dietary changes and 
physical inactivity, must also be taken into account [6]. 
In accordance with other studies, we found dramatically 
reduced markers of bone formation expressed P1NP 
and OC concentrations at ALL diagnosis [5, 8–10]. 
As P1NP reflects the newly synthesized collagen type 1, 
it suggests that bone formation in this disease in children 
and adolescents is strongly negatively affected. Sluis 
et al. [8]. measured bone alkaline phosphatase and P1NP 
as bone formation markers and they showed significant-
ly lower concentrations at diagnosis, which increased 
during follow up of the treatment. In children treated 
for ALL, lower bone alkaline phosphatase may suggest 
impaired osteoblast differentiation resulting from a di-
rect effect of chemotherapy on bone [9]. Contrary to 
our results, they showed normal concentration of bone 
resorption marker — ICTP [8]. Our results, which are 
similar to those reported by Crofton et al. [9], indicated 
reduced bone resorption markers (CTX and TRAP5b) 
at onset of ALL, however, to a much lesser degree than 
markers of bone formation. Very recent data by Yang 
et al. [11] suggest that in acute lymphoblastic leukemia 
the osteogenic differentiation of bone mesenchymal stem 
cells, from which osteoblasts originate, may be inhibited, 
which results in a decreased number of osteoblasts. 
The low bone turnover may be caused by the 
disease itself. It seems, however, that in children and 
adolescents at diagnosis of ALL the coupling between 
resorption and formation processes is still maintained 
to some extent in spite of the fact that bone formation 
appears to be more affected. Osteoporosis and osteo-
penia are a significant problem in children with acute 
leukemia not only at diagnosis but also after chemo-
therapy [10, 12]. 
We are aware of the limitations of this study, small 
number of participants and lack of bone mineral density 
(BMD) and vitamin D status data. However, we evaluat-
ed bone turnover with the use of the recommended and 
sensitive biomarkers and analyzed our data in respect 
of the age of the patients as this is an important factor 
to be considered for the proper interpretation of bone 
marker results.
Conclusions
Acute lymphoblastic leukemia influences bone 
metabolism which is related to the age of onset. More 
significant disturbances in bone turnover, particularly in 
bone formation (suppression of collagen synthesis), are 
observed in children with untreated ALL in comparison 
with ALL adolescents.
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